Recce Pharmaceuticals Director Alistair McKeough to Retire at 6 November 2026 AGM

Aditi Sarkar

04 November 2026 06:50 PM AEDT

Recce Pharmaceuticals Director Alistair McKeough to Retire at 6 November 2026 AGM

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Recce Pharmaceuticals Ltd (ASX:RCE) has disclosed that Independent Non-Executive Director Mr Alistair McKeough has informed the Board of his decision to retire at the conclusion of the Company's Annual General Meeting to be held on Friday, 6 November 2026, and will not seek re-election as a Director of the Company.

Key Points

Mr Alistair McKeough, Independent Non-Executive Director, will retire at the conclusion of the AGM on 6 November 2026 and will not seek re-election.
Resolution 6 (Re-election of Mr Alistair McKeough as a Director) has been withdrawn and will not be put to the AGM; any proxy votes lodged on Resolution 6 will be disregarded.
Mr McKeough served as Chair of the Audit and Risk Committee during his tenure on the Board.
Dr Alan Dunton will assume the role of Chair of the Audit and Risk Committee, effective from the conclusion of the AGM.

McKeough Retirement Details

According to the filing, dated 4 November 2026, Mr McKeough notified the Board of his decision to retire at the conclusion of the Company's AGM scheduled for Friday, 6 November 2026. As a result, Resolution 6, which concerned the re-election of Mr McKeough as a Director and was set out in the Notice of Meeting, has been withdrawn and will not be presented to shareholders at the AGM. The filing states that any proxy votes already lodged in relation to Resolution 6 will be disregarded.

Board Statements on McKeough's Departure

Executive Chairman Dr John Prendergast said in the filing: "I would like to thank Alistair on behalf of the Board for his invaluable counsel, commitment and significant contribution to Recce. He has made a lasting impact on the Company, both as a Director and as Chair of the Audit and Risk Committee. It has been a pleasure working alongside him over the past eight years. We wish Alistair every success in the future." Mr McKeough said: "It has been a challenging but rewarding role with the Company. I extend my best wishes to the Board and the entire Recce team as they work to bring Recce's anti-infectives to market."

Audit and Risk Committee Chair Transition

The filing states that Dr Alan Dunton will assume the role of Chair of the Audit and Risk Committee, effective from the conclusion of the AGM on 6 November 2026. The transition follows Mr McKeough's retirement from the Board. Recce Pharmaceuticals is described in the filing as a developer of a new class of Synthetic Anti-Infectives, with its pipeline including three patented broad-spectrum synthetic polymer anti-infectives: RECCE® 327, RECCE® 435, and RECCE® 529, targeting bacterial and viral infections.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.